Positrigo receives approval for NeuroLF in the USA

Zurich – Positrigo has received marketing authorization from the US Food and Drug Administration (FDA) for its brain PET NeuroLF. This will enable the company to meet strong demand for these diagnostic imaging devices in the USA.

Positrigo has received approval from the US Food and Drug Administration (FDA) for its NeuroLF brain PET, according to a statement from the nuclear imaging device company. The company, which is based in Technopark Zurich, has developed the compact positron emission tomography (PET) device. This means that patients can also undergo a brain scan in smaller treatment units while seated. The NeuroLF is used to diagnose and monitor neurodegenerative diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), epilepsy, tumors and others. According to the press release, the diagnostics previously used for heart diseases can also be easily transferred to brain diseases. The current approval enables broad market access, as new therapies for the treatment of Alzheimer's disease were approved at the same time.

"It's not the first device of its kind to receive market approval in the USA," Dr. Jannis Fischer, co-founder and CEO at Positrigo, was quoted in the announcement. "However, the company believes that our patient-centered and customer-oriented design and development efforts over the years have positioned us in the pole position to offer the best imaging solution to meet the increased demand for brain PET scans. We are excited to fulfill numerous pre-orders in the USA and soon have our first customers benefiting from our technology. I couldn't be prouder of our team, which has tirelessly worked to achieve this significant milestone."

With the FDA approval that has now been granted, Positrigo, a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH) founded in 2018, has reached an important milestone, according to the press release. ce/ww

View full article